Artiva Biotherapeutics, Inc.
ARTV
$4.17
$0.235.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.32% | 3.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.88% | 21.37% | |||
| Operating Income | -2.88% | -21.37% | |||
| Income Before Tax | -4.64% | -26.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.64% | -26.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.64% | -26.19% | |||
| EBIT | -2.88% | -21.37% | |||
| EBITDA | -2.91% | -22.04% | |||
| EPS Basic | -4.48% | -26.42% | |||
| Normalized Basic EPS | -4.49% | 41.08% | |||
| EPS Diluted | -4.48% | 36.86% | |||
| Normalized Diluted EPS | -4.49% | 41.08% | |||
| Average Basic Shares Outstanding | 0.15% | -0.18% | |||
| Average Diluted Shares Outstanding | 0.15% | -0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||